deaths (OS)progression or deaths (PFS)RFS/DFS

mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 2 certainty unassessable-12% certainty unassessable-13%-